A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

NCT02340975 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

114

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

BIOLOGICAL: MEDI4736 + tremelimumab
BIOLOGICAL: MEDI4736 + tremelimumab
BIOLOGICAL: MEDI4736
BIOLOGICAL: Tremelimumab
BIOLOGICAL: MEDI4736+tremelimumab
BIOLOGICAL: MEDI4736 + tremelimumab

Sponsor

MedImmune LLC